MED 最新10-Q变化
将 MED 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-10-26 与上一份 10-Q · 2026-08-03
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +48 | −29 | ~7 | 34 |
| 市场风险(第3项) | 文字有新增/删除 | +40 | −27 | ~26 | 42 |
| 控制与程序 | 文字有新增/删除 | +40 | −27 | ~26 | 42 |
| 法律诉讼 | 文字有新增/删除 | +40 | −27 | ~26 | 42 |
| 风险因素 | 文字有新增/删除 | +40 | −27 | ~26 | 42 |
| 其他信息 | 文字有新增/删除 | +40 | −27 | ~26 | 41 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-10-26
Medifast (“Medifast,” the “Company,” “we,” or “us”) is the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy™. Designed to help address the challenges of metabolic dysfunction, the Company’s holistic approach integrates science-backed p…
The Company started 2026 by executing on its recently unveiled focus on holistic metabolic health, leveraging its extensive experience in structured weight loss coupled with recent scientific research and enhanced product offerings to address the needs of a broader metabolic health market. In July 2…
Our scientifically developed products and habit creation framework, reinforced by coaches and community support, provide proven health benefits and serve as a promising foundation to develop a comprehensive metabolic health system. We continuously innovate and build upon our scientific and clinical …
through metabolic science and human connection. Coaches provide unparalleled support along with community, nutrition, and healthy habits. In a world where health and well-being can often be a difficult and solitary journey, our comprehensive system offers intensely personalized support to individual…
Science has always been integral to Medifast’s identity. Through ongoing research and compelling data that elevate the science behind the Company’s plans and innovative products, the Company is energizing its coach community to empower individuals to take control of their metabolic health. Metabolic…
相对上期删除的文字 · 来源:10-Q · 2026-08-03
Medifast, Inc. (“Medifast,” the “Company,” “we” or “us”) is the health and wellness company known for its science-backed, comprehensive metabolic health system. In October 2025, Medifast announced its strategic transformation, unveiling its focus on holistic metabolic health. The Company started 202…
loss to address the broader metabolic health challenges impacting more than 90% of U.S. adults today. Medifast’s approach focuses on addressing the root cause of metabolic dysfunction. This strategic shift targets a larger and what is believed to be a more sustainable market, focusing on a long-term…
Our scientifically developed products and habit creation framework, reinforced by coaches and community support, provide proven health benefits and serve as a promising foundation to develop a comprehensive metabolic health system. We continuously innovate and build upon our scientific and clinical …
Metabolic health, often misunderstood or overlooked, refers to the body’s ability to efficiently convert food into energy and regulate critical bodily functions. Metabolic dysfunction is a state that can often go unnoticed, placing strain on the body’s metabolic processes and potentially leading to …
Science has always been integral to Medifast’s identity. Through ongoing research and compelling data that elevate the science behind the Company’s plans and innovative products, the Company is energizing its coach community to empower individuals to take control of their metabolic health. In July 2…
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-10-26
Three months ended September 30,Nine months ended September 30,
Three months ended September 30,Nine months ended September 30,
Unrealized net gains (losses) on investment securities(428)41 (651)40
Non-cash restructuring charges, excluding share-based compensation10,832—
Proceeds from sale and maturities of investment securities114,71752,780
相对上期删除的文字 · 来源:10-Q · 2026-08-03
(U.S. dollars in thousands, except per share amounts & dividend data)
Unrealized net losses on investment securities(22)(60)(222)(1)
Proceeds from sale and maturities of investment securities74,84345,265
Net cash flow provided by (used in) investing activities(18,366)11,303
Increase (decrease) in cash and cash equivalents(17,393)10,766
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-10-26
Three months ended September 30,Nine months ended September 30,
Three months ended September 30,Nine months ended September 30,
Unrealized net gains (losses) on investment securities(428)41 (651)40
Non-cash restructuring charges, excluding share-based compensation10,832—
Proceeds from sale and maturities of investment securities114,71752,780
相对上期删除的文字 · 来源:10-Q · 2026-08-03
(U.S. dollars in thousands, except per share amounts & dividend data)
Unrealized net losses on investment securities(22)(60)(222)(1)
Proceeds from sale and maturities of investment securities74,84345,265
Net cash flow provided by (used in) investing activities(18,366)11,303
Increase (decrease) in cash and cash equivalents(17,393)10,766
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-10-26
Three months ended September 30,Nine months ended September 30,
Three months ended September 30,Nine months ended September 30,
Unrealized net gains (losses) on investment securities(428)41 (651)40
Non-cash restructuring charges, excluding share-based compensation10,832—
Proceeds from sale and maturities of investment securities114,71752,780
相对上期删除的文字 · 来源:10-Q · 2026-08-03
(U.S. dollars in thousands, except per share amounts & dividend data)
Unrealized net losses on investment securities(22)(60)(222)(1)
Proceeds from sale and maturities of investment securities74,84345,265
Net cash flow provided by (used in) investing activities(18,366)11,303
Increase (decrease) in cash and cash equivalents(17,393)10,766
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-10-26
Three months ended September 30,Nine months ended September 30,
Three months ended September 30,Nine months ended September 30,
Unrealized net gains (losses) on investment securities(428)41 (651)40
Non-cash restructuring charges, excluding share-based compensation10,832—
Proceeds from sale and maturities of investment securities114,71752,780
相对上期删除的文字 · 来源:10-Q · 2026-08-03
(U.S. dollars in thousands, except per share amounts & dividend data)
Unrealized net losses on investment securities(22)(60)(222)(1)
Proceeds from sale and maturities of investment securities74,84345,265
Net cash flow provided by (used in) investing activities(18,366)11,303
Increase (decrease) in cash and cash equivalents(17,393)10,766
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-10-26
Three months ended September 30,Nine months ended September 30,
Three months ended September 30,Nine months ended September 30,
Unrealized net gains (losses) on investment securities(428)41 (651)40
Non-cash restructuring charges, excluding share-based compensation10,832—
Proceeds from sale and maturities of investment securities114,71752,780
相对上期删除的文字 · 来源:10-Q · 2026-08-03
(U.S. dollars in thousands, except per share amounts & dividend data)
Unrealized net losses on investment securities(22)(60)(222)(1)
Proceeds from sale and maturities of investment securities74,84345,265
Net cash flow provided by (used in) investing activities(18,366)11,303
Increase (decrease) in cash and cash equivalents(17,393)10,766
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议